Home - Products - Inhibitors & Agonists - Others - Details

YW2036 CAS No.: 2131223-92-0

Chemical Structure : YW2036
CAS No.: 2131223-92-0

Send Inquiry

Description

Chemical Structure : YW2036

CAS No.: 2131223-92-0

YW2036

Catalog No.: URK-V2480 Only Used For Lab.

YW2036 main target is the protein kinase B (PKB or AKT) pathway. YW2036 has been shown to inhibit PKB signaling in cancer cells, leading to the inhibition of tumor growth and metastasis.

Biological Activity

YW2036 main target is the protein kinase B (PKB or AKT) pathway. YW2036 has been shown to inhibit PKB signaling in cancer cells, leading to the inhibition of tumor growth and metastasis.
YW2036 has also been found to exhibit activity against other molecular targets involved in cancer development and progression. These include fibroblast growth factor receptor (FGFR), the mammalian target of rapamycin (mTOR), and the extracellular signal-regulated kinase (ERK) pathway.
The inhibitory activity of YW2036 against these molecular targets further adds to its potential in cancer therapeutics.
Several preclinical studies have reported the promising anticancer activity of YW2036 both in vitro and in vivo. For instance, one study found that YW2036 exhibited potent growth inhibition and apoptosis induction in lung cancer cells. Another study found that YW2036 was able to suppress tumor growth and metastasis in a mouse model of breast cancer.

Physicochemical Properties

M.Wt	328.37
Formula	C₂₀H₁₆N₄O
CAS No.	2131223-92-0
Appearance	Solid
Storage	Solide Powder -20 °C 3years; 4°C 2years	In Solvent -80°C 6 Months -20°C 1 Months
Solubility
Chemical Name

References

1. Tian T, Xu L, Tang Q, et al. YW2036, a novel AKT inhibitor, suppresses proliferation and induces apoptosis in lung cancer cells. Anti-Cancer Drugs. 2020;31(4):317-325.

2. Han R, Li Y, Zhang Y, et al. YW2036, a novel AKT inhibitor, inhibits tumor growth and metastasis in breast cancer. Biochem Biophys Res Commun. 2021;534:305-311.